Incorporate enhanced requirements for monitoring pregnancy-specific safety signals into existing pharmacovigilance practices.
MAHs are advised to incorporate the updated FAQs into their compliance workflows and ensure that their submissions adhere to the updated guidance.
CTIS users are now required to actively monitor notifications daily to ensure timely awareness of safety-related tasks.
Pharmacovigilance teams must adopt a structured classification approach to risk analysis, impacting how cases are assessed and notified.
Stakeholders must integrate the new guidance into their signal management and literature surveillance processes to ensure compliance with updated PMDA expectations.
Organizations must update their adverse event reporting processes to align with the clarified classification of borderline products effective immediately.
MAHs must align their workflows to accommodate the updated requirements for signal management and ICSR submissions as per the discussions in the ISG meeting.
Implement mandatory quality checks and oversight for all AI-generated inspection responses to meet MHRA expectations for accuracy.
